Patent: 9,150,848

Summary for Patent: 9,150,848

Title:	Conjugated factor VIII molecules
Abstract:	The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.
Inventor(s):	Bolt Gert, Vandahl Brian Berg Stidsen, Thim Lars, Stennicke Henning Ralf, Steenstrup Thomas Dock, DeFrees Shawn
Assignee:	Novo Nordisk A/s
Application Number:	US14272726
Patent Claims:	see list of patent claims

United States Patent 9,150,848 Claims and Patent Landscape Analysis (US9150848B2)

Executive summary

US 9,150,848 (US9150848B2) sits in a dense US patent neighborhood where parallel continuations and improvement filings commonly extend protection on (i) core subject matter, (ii) specific embodiments, and (iii) manufacturing or formulation variants. The patent landscape around US 9,150,848 typically involves: (a) earlier priority patents from the same family that define the broad inventive concept, (b) later continuation or divisional filings by the same assignee that narrow to particular device/process parameters, and (c) potential “design-around” risk from third-party patents covering adjacent claim elements. However, a complete, claim-by-claim infringement and validity mapping cannot be produced from the prompt because the claim text is missing (“The claims are:” is blank). No accurate analysis of claim scope, key limitations, enforceability, or competitive design-around position can be completed without the actual asserted claims.

What is US 9,150,848 (US9150848B2) and what subject matter does it cover?

US9150848B2 is a US utility patent with claims defining a specific technical invention. A landscape analysis depends on identifying: active assignee, earliest priority date, technology area (composition vs method vs system), claim type (independent and dependent), and whether the patent is part of a family with continuations that broaden or narrow scope.

What are the earliest priority, filing, and issuance dates for US9150848B2?

A claim-level landscape requires the patent bibliographic record (application filing date, priority date, issuance date, and continuation/divisional history). Without the bibliographic record and without the claim text, it is not possible to lock the timeline used for freedom-to-operate and validity analysis.

Who is the assignee and what family members exist?

The landscape hinges on assignee and family structure:

• Same-assignee continuations (often extend coverage to specific embodiments).
• Same-inventor continuations (often preserve earlier priority while changing claim scope).
• Cross-assigned or licensed companion filings (often show where prosecution narrowed scope).

Without the assignee and family list, a critical analysis would be speculative and would not meet the requirement for actionable accuracy.

What patents protect the same invention as US 9,150,848 in the US?

A robust competitor or litigation landscape must identify:

• Prior art patents and publications in the same technical field.
• Same-family blocking patents that cover alternative embodiments.
• Third-party patents that overlap the claim limitations.

Which prior patents most likely anticipate or render obvious the US9150848B2 claims?

To identify anticipating/obviousness risk, the claim limitations must be available. For each independent claim element, the analysis should:

• extract claim limitations,
• map each to candidate prior art disclosures,
• flag missing limitations and partial overlaps,
• assess whether combinations would be motivated.

Without claim text, this mapping cannot be performed.

How many US patents are in the same “blocking” cluster?

A quantitative landscape normally counts:

• same-family US grants,
• continuations/divisionals,
• cited patents by examiner,
• co-cited CPC classes.

This depends on the patent’s full text and prosecution history, which are not present in the prompt.

How strong is the patent estate for US9150848B2 across continuations and divisionals?

Patent strength is driven by:

• independent claim breadth,
• dependent claim density and variety,
• prosecution history (narrowing, amendments, examiner rejections),
• whether claims survive post-grant review,
• whether terminal disclaimers exist.

Does US9150848B2 have continuation-based “evergreen” coverage?

Evergreening is assessed by checking continuation/divisional chain and publication family size. Without family data, it cannot be evaluated.

What claim scope indicators affect enforceability?

Key indicators include:

• claim drafting style (means-plus-function vs structural limitations),
• explicit ranges/thresholds,
• defined functional language and whether it is tied to structure in the specification,
• multiple alternatives inside single claims (which can create interpretation risk).

These require claim text.

What are the key limitations in the asserted claims of US 9,150,848?

This section is the foundation for every later analysis: validity, infringement, design-around, and settlement risk.

What do the independent claims cover?

The prompt states “The claims are:” but the claim list is not provided. With no claim text, it is impossible to:

• identify the “core inventive concept” from claim construction,
• determine which elements are likely to be infringed by product/process implementations,
• determine which elements are likely to be most vulnerable to novelty or non-obviousness attacks.

Which dependent claims add meaningful scope or narrowing?

Dependent claims often:

• lock in preferred parameter ranges,
• add structural or procedural steps that are harder to design around,
• create alternative claim coverage that can preserve validity even if the broad independent claim is challenged.

Without the claim set, this cannot be assessed.

Does US 9,150,848 face validity risks like IPR, PGR, or district court challenges?

A validity risk analysis needs:

• whether US9150848B2 has been asserted,
• whether it has been challenged via IPR/PGR,
• outcomes of any instituted petitions,
• cited references and arguments.

Has US9150848B2 been challenged at the PTAB?

PTAB outcomes materially affect enforceability and settlement leverage. No challenge record is provided.

What prior art has been used to attack similar patents in this space?

A substitute general discussion would not satisfy the required “hard data and actionable insights” standard.

What is the Orange Book status of US 9,150,848, and does it relate to an approved drug?

Orange Book status applies only to patents listed for approved drugs. Without drug name, active ingredient, NDC mapping, or Orange Book listings tied to US9150848B2, this cannot be answered.

Is US9150848B2 listed for an NDA, ANDA, or 505(b)(2)?

This requires the Orange Book patent listing entry. No listing information is included in the prompt.

What generic entry risks exist for products that practice the US9150848B2 claims?

Generic or biosimilar entry risk requires:

• identification of the marketed reference product,
• knowledge of dosage forms or device components involved,
• mapping of each claim limitation to generic design,
• whether the claim set includes formulation, method-of-use, or manufacturing steps.

No drug/product context is provided.

How does US 9,150,848 compare with nearby patents that cover similar subject matter?

A critical comparison typically builds a matrix:

• left column: US9150848B2 independent claim elements,
• columns: competing patents by title/assignee,
• cells: mapping whether each patent discloses each element,
• highlight overlaps and gaps.

No competing patent list or claim elements are available.

If a competitor wanted to design around US 9,150,848, which claim elements are most likely to be avoided?

Design-around guidance is claim-element dependent. Without the claims, the only possible answer would be generic and non-actionable.

Common design-around vectors used in adjacent technology

These vary by field:

• alternative architectures or materials,
• substituting a different parameter range,
• removing a functional step,
• swapping process order,
• using a different mechanism.

But identifying which are plausible for US9150848B2 requires claim text.

What patent litigation affects US 9,150,848 and how does it impact business risk?

A litigation landscape requires:

• case caption(s),
• venue,
• asserted claim numbers,
• accused products/processes,
• injunction requests,
• claim construction orders,
• whether stays or settlements occurred.

No litigation record is provided.

Key timeline: when does US9150848B2 expire and what exclusivity boundaries exist?

For utility patents, expiration analysis uses:

• earliest non-provisional filing,
• adjustment (if any),
• terminal disclaimers,
• continuation chain effects,
• any reexamination/term adjustments.

No bibliographic record is provided, so a deterministic expiration date cannot be stated.

What is the expected expiration date under 35 USC 154?

Not available from the prompt.

How do term adjustments and disclaimers change risk?

Not available from the prompt.

Commercial relevance: what revenue exposure is tied to US 9,150,848?

Revenue exposure depends on:

• identifying the protected product or technology,
• market share and revenue of practice,
• customer adoption,
• switching costs.

No product or technology mapping is provided.

---

Key Takeaways

• A complete, critical analysis of US 9,150,848 requires the actual claim text; the prompt does not include it.
• Without claims, the analysis cannot: (i) identify core limitations, (ii) map prior art, (iii) assess infringement/design-around risk, (iv) evaluate PTAB/district validity vulnerability, or (v) compute enforceable scope accurately.
• The patent landscape can only be meaningfully quantified once claim elements, assignee/family, and cited references are known.

FAQs

1. What is the earliest priority date of US 9,150,848 and how does it affect prior-art lookback?
2. Which claim limitations typically determine infringement scope for US utility patents like US9150848B2?
3. How do continuations and divisionals in the same family expand or narrow coverage versus US9150848B2?
4. What is the most common PTAB argument pattern used to invalidate similar utility patents in the same technical class?
5. How do terminal disclaimers and patent term adjustments affect the real-world enforcement window of US9150848B2?

---

References

1. (No sources cited because no claim text, bibliographic record, assignee, family members, or prosecution/litigation materials were provided in the prompt.)

Details for Patent 9,150,848

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Novo Nordisk Inc.	ESPEROCT	antihemophilic factor (recombinant), glycopegylated-exei	For Injection	125671	February 19, 2019	9,150,848	2034-05-08

International Patent Family for US Patent 9,150,848

Country	Patent Number	Estimated Expiration
South Africa	201005556
World Intellectual Property Organization (WIPO)	2009108806
United States of America	8536126